Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.42 |
| ▸ | KDR | P35968 | 12/20 | 0.42 |
| ▸ | MST1R | Q04912 | 12/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15889701 | 0.83 | MET (0.46) | METKDR | |
| SCHEMBL14273752 | 0.82 | MET (0.44) | METKDRMST1RAURKAFPR1 | |
| SCHEMBL306285 | 0.81 | MET (0.43) | METKDRMST1RAURKAFPR1 | |
| SCHEMBL306566 | 0.78 | MET (0.44) | METKDRMST1RAURKAFPR1 | |
| SCHEMBL15218381 | 0.76 | MET (0.39) | METKDRMST1R | |
| SCHEMBL15218383 | 0.73 | MAP3K8 (0.44) | — | |
| SCHEMBL3577872 | 0.72 | MET (0.53) | METKDRMST1RAURKAFPR1 | |
| SCHEMBL12806955 | 0.71 | GRIN3B (0.35) | — | |
| SCHEMBL2602165 | 0.71 | PDPK1 (0.49) | — | |
| SCHEMBL15218385 | 0.71 | PIK3CA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20130225581-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225581-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE | FGFR3, FGFR1, FGFR4 | MET 35/4885KDR 48/4885MST1R 400/4885 |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | MET, PDXK, FLT3 | MET 1/4885KDR 223/4885MST1R 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.